Merck & Co. Stock Surges Amid Analyst Upgrades and Pipeline Optimism
Merck & Co.'s stock price has been on the rise, reaching $146.63 on September 20, 2026, a significant gain for the pharmaceutical company valued at approximately $362.11 billion.
The stock is trading near the upper half of its 52-week range, having moved between an intraday low of $145.74 and a high of $147.84 before stabilizing around $146.63 in regular trading on the New York Stock Exchange.
A recent fundamental analysis notes that Merck & Co. trades at about 117.5 times trailing earnings, a level described as roughly 42 percent above its five-year median price-to-earnings multiple, with investors anticipating a sharp recovery in profitability.
However, the company's revenue growth has been modest, with a year-on-year increase of only 4.6 percent, and operating margin compressing to 10.5 percent from an average of 22.4 percent over the prior three years.